Novavax Appoints Biotechnology Veteran David Mott to Board of Directors

GAITHERSBURG, Md., June 16 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has appointed David Mott as an independent director to its Board of Directors. Mr. Mott brings more than three decades of global management, board and investment experience across numerous [...]